SYDNEY WELT
Medical Practice in Armonk, NY
License number
Pennsylvania MD423962
Category
Medicine
Type
Medical Physician and Surgeon
Address
Address
2
Armonk, NY 10504
Pennsylvania
Pennsylvania
Professional information
Dr. Sydney Welt, Elmira NY - MD (Doctor of Medicine)
Specialties:
Oncology, Medical Oncology
Address:
555 Saint Josephs Blvd, Elmira 14901
(607) 737-7814 (Phone), (607) 271-3430 (Fax)
59 Whippoorwill Xing, Armonk 10504
(607) 737-7814 (Phone), (607) 271-3430 (Fax)
59 Whippoorwill Xing, Armonk 10504
Certifications:
Internal Medicine, 1980, Medical Oncology, 1983
Awards:
Healthgrades Honor Roll
Languages:
English
Hospitals:
555 Saint Josephs Blvd, Elmira 14901
59 Whippoorwill Xing, Armonk 10504
Corning Hospital
176 Denison Pkwy East, Corning 14830
59 Whippoorwill Xing, Armonk 10504
Corning Hospital
176 Denison Pkwy East, Corning 14830
Education:
Medical School
New York University
Graduated: 1977
Albert Einstein Coll Med
Meml Sloan-Kettering Cancer
New York University
Graduated: 1977
Albert Einstein Coll Med
Meml Sloan-Kettering Cancer
Recombinant Human Anti-Lewis B Antibodies
US Patent:
5795961, Aug 18, 1998
Filed:
Feb 14, 1995
Appl. No.:
8/388672
Inventors:
T. Paul Wallace - Aberdeenshire, GB3
William J. Harris - Carnoustie, GB3
Frank J. Carr - Balmedie, GB3
Lloyd J. Old - New York NY
Sydney Welt - Armonk NY
Kunio Kitamura - Nagoya, JP
William J. Harris - Carnoustie, GB3
Frank J. Carr - Balmedie, GB3
Lloyd J. Old - New York NY
Sydney Welt - Armonk NY
Kunio Kitamura - Nagoya, JP
Assignee:
Ludwig Institute for Cancer Research - New York NY
International Classification:
C07K 1400, A61K 3816, C12P 2108
US Classification:
530350
Abstract:
The invention provides for the production of several humanized murine antibodies specific for the Lewis b antigen, which is recognized by the murine antibody 58-1066. The antigen is expressed on cell lines from colon, lung, bladder, breast, renal, pancreatic and ovarian cancers. The expression of the antigen is greatly increased in cancer tissues as compared to its expression in the corresponding normal tissue. The invention also provides for numerous polynucleotide encoding humanized Lewis b antigen specific antibodies, expression vectors for producing humanized Lewis b antigen specific antibodies, and host cells for the recombinant production of the humanized antibodies. The invention also provides methods for detecting cancerous cells (in vitro and in vivo) using humanized Lewis b antigen specific antibodies. Additionally, the invention provides methods of treating cancer using Lewis b antigen specific antibodies.
Isolated Nucleic Acid Molecules Which Encode Human Anti-Lewis B Antibodies
US Patent:
6025481, Feb 15, 2000
Filed:
May 18, 1998
Appl. No.:
9/080554
Inventors:
T. Paul Wallace - Aberdeenshire, GB
William J. Harris - Carnoustie, GB
Frank J. Carr - Balmedie, GB
Lloyd J. Old - New York NY
Sydney Welt - Armonk NY
Kunio Kitamura - Nagoya, JP
William J. Harris - Carnoustie, GB
Frank J. Carr - Balmedie, GB
Lloyd J. Old - New York NY
Sydney Welt - Armonk NY
Kunio Kitamura - Nagoya, JP
Assignee:
Memorial Sloan-Kettering Cancer Center - New York NY
International Classification:
C07H 2102, C12N 120, C12N 1500, C12N 500
US Classification:
536 231
Abstract:
The invention provides for the production of several humanized murine antibodies specific for the Lewis b antigen, which is recognized by the murine antibody 58-1066. The antigen is expressed on cell lines from colon, lung, bladder, breast, renal, pancreatic and ovarian cancers. The expression of the antigen is greatly increased in cancer tissues as compared to its expression in the corresponding normal tissue. The invention also provides for numerous polynucleotide encoding humanized Lewis b antigen specific antibodies, expression vectors for producing humanized Lewis b antigen specific antibodies, and host cells for the recombinant production of the humanized antibodies. The invention also provides methods for detecting cancerous cells (in vitro and in vivo) using humanized Lewis b antigen specific antibodies. Additionally, the invention provides methods of treating cancer using Lewis b antigen specific antibodies.
Immunoglobulin Associated Cell-Surface Determinants In The Treatment Of B-Cell Disorders
US Patent:
2009022, Sep 3, 2009
Filed:
May 3, 2007
Appl. No.:
12/298781
Inventors:
Sydney Welt - Armonk NY, US
David A. Kostyal - Sayre PA, US
David A. Kostyal - Sayre PA, US
International Classification:
A61K 51/10, A61K 39/395, C12Q 1/68, C12Q 1/00
US Classification:
424 149, 4241311, 435 6, 435 4
Abstract:
The present invention provides methods, compositions and vaccines for specifically targeting immunoglobulin associated cell-surface determinants that are not shed into the blood of a host. In some cases, the immunoglobulin associated cell-surface determinants will be involved in various B-cell disorders. The methods involve administering an IACSD targeting element to a B-cell. The method can employ treating an individual with a B-cell associated disorder by administering an effective amount of an IACSD targeting preparation. The compositions include isolated antibodies where the antibodies associate with an immunoglobulin associated cell-surface determinants. The invention also includes vaccines that immunize against immunoglobulin associated cell-surface determinants.
Hybridoma Cell Lines Which Produce Monoclonal Antibodies Having The Properties Of Monoclonal Antibody 100-310 And The Monoclonal Antibodies Produced By These Hybridoma Cell Lines
US Patent:
5565356, Oct 15, 1996
Filed:
Jul 11, 1994
Appl. No.:
8/273277
Inventors:
Sydney Welt - Armonk NY
Clarence Williams - Riverdale NY
Elsje C. Barendswaard - New York NY
Chaitanya R. Divgi - New York NY
Lloyd J. Old - New York NY
Clarence Williams - Riverdale NY
Elsje C. Barendswaard - New York NY
Chaitanya R. Divgi - New York NY
Lloyd J. Old - New York NY
Assignee:
Memorial Sloan-Kettering Cancer Center - New York NY
International Classification:
C12N 520, C07K 1630
US Classification:
43524027
Abstract:
Monoclonal antibody 100-310 is found to be reactive against colon cancer cells and would therefore be useful for diagnostic imaging and treatment of colon cancer.